Phase 2 Study of Pembrolizumab and Circulating Biomarkers to Predict Anticancer Response in Advanced, Unresectable Hepatocellular Carcinoma

BACKGROUND: Checkpoint inhibitors have shown modest activity in patients with advanced hepatocellular carcinoma (HCC). Herein, the authors report a prospective single-institution clinical/translational phase 2 study of pembrolizumab in patients with advanced HCC and circulating biomarkers closely re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Feun, Lynn G., Li, Ying-Ying, Wu, Chunjing, Wangpaichitr, Medhi, Jones, Patricia D., Richman, Stephen P., Madrazo, Beatrice, Kwon, Deukwoo, Garcia-Buitrago, Monica, Martin, Paul, Hosein, Peter J., Savaraj, Niramol
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592647/
https://ncbi.nlm.nih.gov/pubmed/31251403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32339
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados